Amid efficacy row, Covaxin gets thumbs-up from Lancet
Amid a raging controversy over the efficacy of Covaxin, India’s first indigenous Covid-19 vaccine, reputed medical journal the Lancet Infectious Diseases on Friday said the vaccine produced tolerable safety outcomes and enhanced immune responses in its Phase 1 trials.
You Might Like
💡 newsR Knowledge: Other News Mentions
Lancet publishes Covaxin phase 2 trials dataprestigious medical journal The Lancet has now published Phase 2 clinical trial results of Bharat Biotech's Covaxin. "Due to the difference in dosing regimens..
Mexico experts recommend approving Indian vaccineA technical committee of experts in Mexico gave a unanimous favorable opinion Friday on approving the Covaxin vaccine made by the Indian pharmaceutical company..
Govt sees Covaxin efficacy as validation of its scientific processThe phase 3 results of Covaxin released on Wednesday showing 81% efficacy is seen by the government as a major validation of the scientific process and..
Covid vaccine explained: Covishield? Covaxin? Do's and Don'ts | Oneindia News
Credit: Oneindia Duration: 03:13Published
'Majority' of ITV shows back in production as COVID knocks profitsITV says a "majority" of the programmes it makes are now back in production after coronavirus disruption knocked 2020 profits by a fifth.
COVID-19: India reports 15,388 new cases, 77 deaths in last 24 hrs
Credit: ANI Duration: 01:48Published
100 saints get COVID jab at Swaminarayan temple in Gujarat
Credit: ANI Duration: 01:45Published
Related videos from verified sources
Related news from verified sources